Company intelligence / Profile preview

Orchard Therapeutics

Ownership: Public · ORTX
Employees: ~222
Development stage: Commercial

Overview

Orchard Therapeutics has developed Libmeldy (OTL-200) for MLD which is approved in Europe, with a pending BLA in the US. The company has treated more than 160 patients across six different disease areas with up to 10 years of post-treatment follow-up in some conditions.

Therapeutic areas: HematologyImmunologyRare DiseasesNeurology
Modalities: Ex vivo autologous hematopoietic stem cell (HSC) gene therapy
Industry: Biotech

Drug pipeline

8 assets

atidarsagene autotemcel

Approved

7 more assets in the full pipeline.

Request access →

Partnerships

GSK (acquired GSK's rare disease gene therapy portfolio in 2018)San Raffaele Telethon Institute for Gene Therapy

Financials

Market cap: $380.1M
Total revenue: $6.3M
Enterprise value: $302.5M

Beyond the preview

Go deeper on Orchard Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orchard Therapeutics.

Explore the full profile